Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | IL33 | O95760 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306590 | 1.00 | OPRK1 (0.49) | OPRK1OPRM1HRH3MEN1KMT2A | |
| SCHEMBL23507317 | 0.88 | DRD2 (0.57) | OPRK1OPRM1HRH3MEN1KMT2A | |
| SCHEMBL28519807 | 0.85 | OPRK1 (0.52) | OPRK1OPRM1HRH3MEN1KMT2A | |
| SCHEMBL8537692 | 0.83 | THRB (0.53) | OPRK1OPRM1HRH3ALDH1A1DRD2 | |
| SCHEMBL18862021 | 0.83 | OPRK1 (0.52) | OPRK1OPRM1HRH3MEN1KMT2A | |
| SCHEMBL11512485 | 0.82 | OPRK1 (0.57) | OPRK1OPRM1HRH3MEN1KMT2A | |
| SCHEMBL8542014 | 0.81 | SMN1; SMN2 (0.50) | OPRK1OPRM1HRH3ALDH1A1DRD2 | |
| SCHEMBL11939036 | 0.80 | DRD2 (0.49) | OPRK1OPRM1HRH3MEN1KMT2A | |
| SCHEMBL11452553 | 0.80 | CHRNB2 (0.56) | OPRK1OPRM1MEN1KMT2AALDH1A1 | |
| SCHEMBL11509465 | 0.79 | OPRK1 (0.58) | OPRK1OPRM1HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | OPRK1 1223/4885OPRM1 1010/4885HRH3 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.